Lantern Pharma

About:

Lantern Pharma is a clinical stage biopharma company developing precision oncology therapies leveraging A.I., machine learning, and genomics

Website: http://www.lanternpharma.com/

Twitter/X: lanternpharma

Top Investors: Health Wildcatters, Green Park & Golf Ventures, Bios Partners

Description:

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action. Lantern also rescues and revitalizes abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent therapy combinations. Our approach, which leverages our RADR™ platform helps to provide rapid, meaningful insight to both of these central problems in oncology. Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.

Total Funding Amount:

$95M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Dallas, Texas, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)lanternpharma.com

Founders:

Arun Asaithambi, Panna Sharma, Peter Nara

Number of Employees:

11-50

Last Funding Date:

2021-01-14

IPO Status:

Public

Industries:

© 2025 bioDAO.ai